Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409496 | 1.00 | TP53 (0.31) | TP53SMN1; SMN2CYP2C19NPC1USP2 | |
| SCHEMBL6409489 | 0.68 | PPIB (0.31) | TP53SMN1; SMN2NPC1USP2RAB9A | |
| SCHEMBL6606317 | 0.66 | KDM4E (0.38) | TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL6408016 | 0.63 | KDM4E (0.35) | TP53SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL6409426 | 0.63 | KDM4E (0.35) | TP53SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL6605887 | 0.63 | KDM4E (0.35) | TP53SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL6606311 | 0.62 | KDM4E (0.37) | TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL8371644 | 0.56 | ESR1 (0.35) | SMN1; SMN2NPC1RAB9AHSD17B10 | |
| SCHEMBL727942 | 0.55 | HSD17B10 (0.56) | SMN1; SMN2CYP2C19NPC1USP2RAB9A | |
| SCHEMBL6402519 | 0.54 | KDM4E (0.41) | TP53SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | TP53 4513/4885SMN1; SMN2 4636/4885CYP2C19 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.